Aligos Therapeutics (ALGS) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 25, 2026, and will be held virtually, with registration required by June 24, 2026.

• Five key proposals will be presented: election of directors, auditor ratification, amendment to the ESPP, advisory say-on-pay, and frequency of say-on-pay votes.

• Only stockholders as of April 27, 2026, are eligible to vote, with 5,388,223 shares outstanding and entitled to vote.

• Voting can be done online, by phone, or by mail, and results will be announced via Form 8-K.

Voting matters and shareholder proposals

• Proposal 1: Elect two Class III directors (Bridget Martell and Carole Nuechterlein) for terms expiring in 2029.

• Proposal 2: Ratify Ernst & Young LLP as independent auditor for fiscal year 2026.

• Proposal 3: Amend the ESPP to remove the evergreen provision and add 500,000 shares to the reserve.

• Proposal 4: Advisory vote on executive compensation (say-on-pay).

• Proposal 5: Advisory vote on frequency of say-on-pay (board recommends every one year).

Board of directors and corporate governance

• Board consists of seven directors divided into three staggered classes, with a majority deemed independent under Nasdaq rules.

• Committees include Audit, Compensation, Nominating and Corporate Governance, and Business Development and Strategy.

• Lead independent director role established; independent directors meet in executive sessions.

• Code of Business Conduct and Ethics and Corporate Governance Guidelines are in place and publicly available.